- Home
- IMUX vs KPLT Comparison
IMUX vs KPLT Comparison
Compare IMUX & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- KPLT
- Stock Information
- Founded
- IMUX 2016
- KPLT 2012
- Country
- IMUX United States
- KPLT United States
- Employees
- IMUX N/A
- KPLT N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- KPLT Diversified Commercial Services
- Sector
- IMUX Health Care
- KPLT Consumer Discretionary
- Exchange
- IMUX Nasdaq
- KPLT Nasdaq
- Market Cap
- IMUX 90.4M
- KPLT 97.4M
- IPO Year
- IMUX N/A
- KPLT N/A
- Fundamental
- Price
- IMUX $0.79
- KPLT $19.42
- Analyst Decision
- IMUX Strong Buy
- KPLT Hold
- Analyst Count
- IMUX 5
- KPLT 1
- Target Price
- IMUX $7.50
- KPLT $10.00
- AVG Volume (30 Days)
- IMUX 1.3M
- KPLT 89.7K
- Earning Date
- IMUX 11-06-2025
- KPLT 11-05-2025
- Dividend Yield
- IMUX N/A
- KPLT N/A
- EPS Growth
- IMUX N/A
- KPLT N/A
- EPS
- IMUX N/A
- KPLT N/A
- Revenue
- IMUX N/A
- KPLT $267,101,999.00
- Revenue This Year
- IMUX N/A
- KPLT $22.88
- Revenue Next Year
- IMUX N/A
- KPLT $10.98
- P/E Ratio
- IMUX N/A
- KPLT N/A
- Revenue Growth
- IMUX N/A
- KPLT 13.04
- 52 Week Low
- IMUX $0.56
- KPLT $5.08
- 52 Week High
- IMUX $2.11
- KPLT $24.34
- Technical
- Relative Strength Index (RSI)
- IMUX 42.07
- KPLT 60.20
- Support Level
- IMUX $0.74
- KPLT $13.25
- Resistance Level
- IMUX $0.90
- KPLT $24.34
- Average True Range (ATR)
- IMUX 0.06
- KPLT 2.19
- MACD
- IMUX -0.00
- KPLT 0.19
- Stochastic Oscillator
- IMUX 25.02
- KPLT 55.64
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.